CA2940455C - Polymyxin derivatives and their use in combination therapy together with different antibiotics - Google Patents

Polymyxin derivatives and their use in combination therapy together with different antibiotics Download PDF

Info

Publication number
CA2940455C
CA2940455C CA2940455A CA2940455A CA2940455C CA 2940455 C CA2940455 C CA 2940455C CA 2940455 A CA2940455 A CA 2940455A CA 2940455 A CA2940455 A CA 2940455A CA 2940455 C CA2940455 C CA 2940455C
Authority
CA
Canada
Prior art keywords
compound
group
nitrogen
carbon
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2940455A
Other languages
English (en)
French (fr)
Other versions
CA2940455A1 (en
Inventor
Pamela Brown
Michael Dawson
Mona SIMONOVIC
Steven Boakes
Esther DUPERCHY
Steven James Stanway
Antoinette Wilson
Stephen Frederick Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spero Therapeutics Inc
Original Assignee
Spero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201404301A external-priority patent/GB201404301D0/en
Priority claimed from GB201421019A external-priority patent/GB201421019D0/en
Application filed by Spero Therapeutics Inc filed Critical Spero Therapeutics Inc
Publication of CA2940455A1 publication Critical patent/CA2940455A1/en
Application granted granted Critical
Publication of CA2940455C publication Critical patent/CA2940455C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2940455A 2014-03-11 2015-03-11 Polymyxin derivatives and their use in combination therapy together with different antibiotics Active CA2940455C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201404301A GB201404301D0 (en) 2014-03-11 2014-03-11 Compounds and combinations
GB1404301.2 2014-03-11
GB201421019A GB201421019D0 (en) 2014-11-26 2014-11-26 Compounds
GB1421019.9 2014-11-26
PCT/EP2015/055046 WO2015135976A1 (en) 2014-03-11 2015-03-11 Polymyxin derivatives and their use in combination therapy together with different antibiotics

Publications (2)

Publication Number Publication Date
CA2940455A1 CA2940455A1 (en) 2015-09-17
CA2940455C true CA2940455C (en) 2023-03-21

Family

ID=52823596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2940455A Active CA2940455C (en) 2014-03-11 2015-03-11 Polymyxin derivatives and their use in combination therapy together with different antibiotics

Country Status (21)

Country Link
US (3) US20170073373A1 (https=)
EP (1) EP3116897B1 (https=)
JP (1) JP6785659B2 (https=)
KR (2) KR20230152779A (https=)
CN (1) CN106232617B (https=)
AU (1) AU2015228898B2 (https=)
CA (1) CA2940455C (https=)
CY (1) CY1125175T1 (https=)
DK (1) DK3116897T3 (https=)
ES (1) ES2910072T3 (https=)
HR (1) HRP20220387T1 (https=)
IL (1) IL247243B (https=)
LT (1) LT3116897T (https=)
MX (1) MX359104B (https=)
PL (1) PL3116897T3 (https=)
PT (1) PT3116897T (https=)
RS (1) RS63138B1 (https=)
RU (1) RU2740190C2 (https=)
SI (1) SI3116897T1 (https=)
TW (1) TWI709575B (https=)
WO (1) WO2015135976A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
JP2017512818A (ja) 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 抗菌性化合物としてのポリミキシン誘導体
US12146004B2 (en) 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
WO2016100578A2 (en) 2014-12-16 2016-06-23 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
CN105030744B (zh) * 2015-07-09 2019-04-19 广州英赛特生物技术有限公司 取代苯胍衍生物作为多粘菌素类抗生素增效剂的应用
EP3356387B1 (en) * 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
JP6744622B2 (ja) * 2016-06-16 2020-08-19 学校法人上智学院 ピペリジン化合物の製造方法
CN111527100A (zh) * 2017-11-02 2020-08-11 昆士兰大学 肽类抗生素
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
WO2022098950A1 (en) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Compounds
JP7621502B2 (ja) 2021-02-02 2025-01-24 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー ビフェニル誘導体化合物を有効成分として含有する抗菌補助剤及びこの用途
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) * 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
CA2747995A1 (en) * 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) * 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
US8415307B1 (en) * 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
KR102354902B1 (ko) * 2013-05-22 2022-01-24 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도

Also Published As

Publication number Publication date
EP3116897A1 (en) 2017-01-18
MX2016011682A (es) 2017-04-27
DK3116897T3 (da) 2022-03-28
KR20230152779A (ko) 2023-11-03
LT3116897T (lt) 2022-05-10
RU2016139978A (ru) 2018-04-13
HRP20220387T1 (hr) 2022-05-27
RU2016139978A3 (https=) 2018-10-17
EP3116897B1 (en) 2022-03-02
US20230322858A1 (en) 2023-10-12
PT3116897T (pt) 2022-04-07
CY1125175T1 (el) 2024-12-13
TWI709575B (zh) 2020-11-11
ES2910072T3 (es) 2022-05-11
SI3116897T1 (sl) 2022-06-30
JP2017510570A (ja) 2017-04-13
RU2740190C2 (ru) 2021-01-12
TW201617362A (zh) 2016-05-16
AU2015228898B2 (en) 2018-11-15
IL247243A0 (en) 2016-09-29
US20170073373A1 (en) 2017-03-16
WO2015135976A1 (en) 2015-09-17
CN106232617A (zh) 2016-12-14
JP6785659B2 (ja) 2020-11-18
CN106232617B (zh) 2022-06-24
KR20160135739A (ko) 2016-11-28
MX359104B (es) 2018-09-14
PL3116897T3 (pl) 2022-05-30
AU2015228898A1 (en) 2016-10-20
CA2940455A1 (en) 2015-09-17
US20210221848A1 (en) 2021-07-22
RS63138B1 (sr) 2022-05-31
IL247243B (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CA2940455C (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
US10407467B2 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
CA2968902C (en) Compounds derived from polymyxin
AU2003245928B2 (en) Antibacterial amide macrocycles
WO2020002325A1 (en) Compounds
US20060258571A1 (en) Antibacterial ester macrocycles
JP2008502583A (ja) 抗細菌性アミド大員環
CA2581527A1 (en) Antibacterial amide macrocycles iv
HK1240940B (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
Farhan et al. SYNTHESIS, CHARACTERIZATION AND ANTIMICROBIAL ACTIVITY OF NEW BENZOXAZOLE AMINO ACID ESTER DERIVATIVES
BR112016020998B1 (pt) Compostos derivados de polimixina, composições farmacêuticas compreendedo os ditos compostos e usos terapêuticos dos mesmos
IL165630A (en) Antibacterial amide macrocycles
HK1083511B (en) Antibacterial amide macrocycles

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200303

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241210

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209